Abstract: Imidazodiazepine derivatives of the formula ##STR1## wherein A together with the two carbon atoms denoted as .alpha. and .beta. is selected from the group consisting of ##STR2## the dotted line represents the double bond present in groups (a) and (b), D is >C.dbd.O or >C.dbd.S, R.sup.1 is selected from the group consisting of cyano, lower alkanoyl and a group of the formula --COOR.sup.4, R.sup.4 is selected from the group consisting of methyl, ethyl, isopropyl and 2-hydroxyethyl, R.sup.5 is selected from the group consisting of hydrogen, trifluoromethyl and halogen and R.sup.6 is selected from the group consisting of hydrogen, trifluoromethyl, halogen and lower alkyl and either R.sup.2 is hydrogen and R.sup.3 is hydrogen or lower alkyl or R.sup.2 and R.sup.3 together are trimethylene or propenylene and the carbon atom denoted as .gamma.

Abstract: Imidazodiazepine derivatives of the formula ##STR1## wherein A together with the two carbon atoms denoted as .alpha. and .beta. is selected from the group consisting of ##STR2## the dotted line represents the double bond present in groups (a) and (b), D is >C.dbd.O or >C.dbd.S, R.sup.1 is selected from the group consisting of cyano, lower alkanoyl and a group of the formula --COOR.sup.4, R.sup.4 is selected from the group consisting of methyl, ethyl, isopropyl and 2-hydroxyethyl, R.sup.5 is selected from the group consisting of hydrogen, trifluoromethyl and halogen and R.sup.6 is selected from the group consisting of hydrogen, trifluoromethyl, halogen and lower alkyl and either R.sup.2 is hydrogen and R.sup.3 is hydrogen or lower alkyl or R.sup.2 and R.sup.3 together are trimethylene or propenylene and the carbon atom denoted as .gamma.

Abstract: There is presented compounds of formula ##STR1## wherein X and Y are hydrogen or halogen and R.sub.1 is lower alkyl or NR.sub.2 R.sub.3wherein R.sub.2 and R.sub.3 are hydrogen or lower alkyland the pharmaceutically acceptable salts thereof.Also presented are novel intermediates and a process to produce the novel end products.The compounds of formula I are useful as anxiolytic and sedative agents.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n --wherein n is 2 to 20, ##STR2## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR3## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n --wherein n is 2 to 20, ##STR4## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof.There are also disclosed processes and intermediates utilized to produce the end products.The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

Abstract: A process to produce a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are selected from the group consisting of the groups C.sub.2 H.sub.5 OOC--, CH.sub.3 OOC-- and N.tbd.C--, with the limitation that R.sub.1 and R.sub.2 cannot both be N.tbd.C--, Y is hydrogen or halogen and X is selected from the group consisting of hydrogen halogen and nitroThe compound is useful as an intermediate in the production of imidazobenzodiazepines, compounds having pharmacological activity.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n-- wherein n is 2 to 20, ##STR2## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR3## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n-- wherein n is 2 to 20, ##STR4## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof.There are also disclosed processes and intermediates utilized to produce the end products.The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

Abstract: There is disclosed compounds of the formula ##STR1## wherein R.sup.1 represents a methyl or acetonyl group and R.sup.2 represents a hydrogen atom, a hydroxyl group or a group of the formula ##STR2## and a process for the preparation thereof. The compounds are useful as intermediates for the preparation of anthracycline antibiotics and certain of the compounds exhibit per se activity as antibacterial and antitumor agents.

Abstract: Acyl derivatives of the formula ##STR1## wherein R signifies hydrogen or a protective group which can be split off, R.sup.1 signifies lower alkyl and X signifies the group ##STR2## wherein one of the residues R.sup.2 and R.sup.3 represents hydrogen and the other represents alkyl and R.sup.4 represents lower alkylthe easily hydrolyzable esters and ethers thereof, the salts and hydrates of the above compounds, esters, ethers and salts.

Abstract: There is presented benzodiazepine derivatives of the formula ##STR1## wherein A is the group ##STR2## R.sup.1 is lower alkyl, R.sup.2 and R.sup.3 each are hydrogen or lower alkyl, R.sup.4 is the group ##STR3## R.sup.5 is hydrogen or halogen, R.sup.8 is hydrogen or lower alkyl, R.sup.9 is lower alkyl or lower alkoxyalkyl, R.sup.10 is lower alkyl, R.sup.11 is hydrogen, lower alkyl or lower hydroxyalkyl, R.sup.12 is hydrogen or lower alkyl and R.sup.14 is lower alkyl or aryl, and either R.sup.6 is hydrogen or lower alkyl and R.sup.7 is lower alkyl or lower hydroxyalkyl or R.sup.6 and R.sup.7 together with the nitrogen atom are a 3- to 7-membered heterocycle which, when it is at least 5-membered, can contain as a ring member an oxygen or sulphur atom or a group of the formula >N-R.sup.13, in which R.sup.13 is hydrogen or lower alkyl, and either R.sup.6 ' is hydrogen or lower alkyl and R.sup.7 ' is lower alkyl or R.sup.6 ' and R.sup.

Abstract: There is presented compounds of formula ##STR1## wherein X and Y are hydrogen or halogen and R.sub.1 is lower alkyl or NR.sub.2 R.sub.3wherein R.sub.2 and R.sub.3 are hydrogen or lower alkyland the pharmaceutically acceptable salts thereof.Also presented are novel intermediates and a process to produce the novel end products.The compounds of formula I are useful as anxiolytic and sedative agents.

Abstract: Compounds of the formula ##STR1## wherein X and Y are selected from the group consisting of hydrogen, halogen and trifluoromethyl, are disclosed.The compounds are useful as intermediates in the production of 2-benzazepines, compounds of pharmacological activity.Also disclosed are other intermediates and processes for their production.

Abstract: Imidazodiazepine derivatives of the formula ##STR1## wherein A together with the two carbon atoms denoted as .alpha. and .beta. is selected from the group consisting of ##STR2## the dotted line represents the double bond present in groups (a) and (b), D is >C.dbd.O or >C.dbd.S, R.sup.1 is selected from the group consisting of cyano, lower alkanoyl and a group of the formula --COOR.sup.4, R.sup.4 is selected from the group consisting of methyl, ethyl, isopropyl and 2-hydroxyethyl, R.sup.5 is selected from the group consisting of hydrogen, trifluoromethyl and halogen and R.sup.6 is selected from the group consisting of hydrogen, trifluoromethyl, halogen and lower alkyl and either R.sup.2 is hydrogen and R.sup.3 is hydrogen or lower alkyl or R.sup.2 and R.sup.3 together are trimethylene or propenylene and the carbon atom denoted as .gamma.

Abstract: There is presented a process for the manufacture of hexahydronaphthacene derivatives of the general formula ##STR1## wherein one of R.sup.1 and R.sup.2 represents a hydrogen atom and the other represents a hydrogen atom or a hydroxy group or R.sup.1 and R.sup.2 together represent a protected oxo group, R.sup.3 represents a hydrogen atom or a hydroxy or acyloxy group and R.sup.4 represents a lower alkyl or esterified carboxy group or a group of the formula ##STR2## wherein R.sup.5 and R.sup.6 together form an oxo group or a protected oxo group and X represents a hydrogen atom or a hydroxy or acyloxy group or ##STR3## in which n stands for 1 or 2 and Y represents a hydrogen atom or an alkyl or acyl group.Also presented are certain of the novel derivatives per se and various novel intermediates in the process.

Abstract: Benzodiazepine derivatives which have tranquillizing activity, especially 1,4-benzodiazepine derivatives, can lower the serum prolactin concentration. They can reduce, dosage-dependently, the increase in the serum prolactin concentration induced by the administration of neuroleptics, which can lead to undesirable side-effects, when about 0.01 to 100 parts by weight of benzodiazepine derivatives are administered per part by weight of neuroleptic, it being immaterial whether the benzodiazepine derivative is administered before or after the neuroleptic or simultaneously therewith. The simultaneous administration of the active substances can be carried out as an ad hoc combination or in the form of a pharmaceutical combination.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n -wherein n is 2 to 20, ##STR2## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR3## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n -- wherein n is 2 to 20, ##STR4## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof.There are also disclosed processes and intermediates utilized to produce the end products.The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

Abstract: A process to produce methyl 3,4-anhydro-2,6-dideoxy-L-ribohexopyranoside, its enantiomer and racemate thereof.The compound is useful as an intermediate in the production of daunosamine which in turn is a prime constituent in the anti-cancer agents Daunomycin and Adriamycin. Also disclosed are novel intermediates in the process.

Abstract: This invention is directed toward pharmacologically active compound of the formula ##STR1## wherein A is ##STR2## R.sub.1 is selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, acyloxy lower alkyl, phenyl, alkoxy lower alkyl, halo lower alkyl, amino lower alkyl, substituted amino lower alkyl, substituted phenyl, pyridyl, aralkyl and the groups ##STR3## wherein R is hydrogen or lower alkyl and ROOC where R is lower alkyl; R.sub.2 is selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, acyloxy lower alkyl, alkoxy lower alkyl, halo lower alkyl, amino or substituted amino lower alkyl, amino, cyano, cyano lower alkyl, substituted amino, chloro, bromo and iodo, the group --COOR where R is hydrogen or lower alkyl, the group ##STR4## where R is hydrogen or lower alkyl, or derivatives thereof, e.g., the group R--C.dbd.

Abstract: There are disclosed compounds of the formula ##STR1## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n -- wherein n is 2 to 20, ##STR2## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy, and ##STR3## wherein R.sub.1 is selected from the group consisting of lower alkyl; R.sub.8 is selected from the group consisting of --O--(CH.sub.2).sub.n -- wherein n is 2 to 20, ##STR4## and R.sub.6 is selected from the group consisting of hydrogen or lower alkoxy and racemates thereof.There are also disclosed processes and intermediates utilized to produce the end products.The end products have utility as agents exhibiting both .alpha. and selective .beta. adrenergic blocking action.

Abstract: A novel antibiotic having the ascribed formula ##STR1## is provided. They physical characteristics are as follows: (a) Elementary analysis: Calculated (for C.sub.20 H.sub.16 O.sub.7): C,65.22; H,4.35%. Found: C,64.60; H,4.34%.(b) Molecular weight (mass-spectrometric): 368.(c) Melting point: 225.degree.-226.degree. C.(d) Specific rotation: [.alpha.].sub.D .sup.20 =+123.5.degree. (c=0.2 in chloroform).(e) Ultraviolet absorption spectrum:.lambda..sub.max .sup.methanol =235 nm (.epsilon.=28600); 262 nm (.epsilon.=21900); 434-435 nm (.epsilon.=11300);.lambda..sub.max .sup.0.1-N NaOH/methanol =246 nm (.epsilon.=22400); 256 nm (.epsilon.=23200); 523-524 nm (.epsilon.=9600).(f) Infrared absorption spectrum: 3500, 1710, 1672, 1628, 1600, 1575, 1472, 1452, 1420, 1390, 1295, 1255, 1218, 1200, 1182, 1105, 1025, 1005, 962, 938, 848, 765, 752, 730 cm.sup.-1.

Abstract: A method is disclosed for the use of polyether ionophores as antiobesity and hypotriglyceridemic agents in warm blooded animals by the administration to an animal in need of such treatment of a therapeutically effective dose of a polyether compound. Also disclosed are examples of such polyether compounds and methods for their preparation.